59-Year-Old Man with MDS  by Deeg, H. Joachim
CLINICAL CHALLENGE1083-8791
doi:10.10159-Year-Old Man with MDSA 59-year-old otherwise healthy male sought medical evaluation because of 3 months of fatigue. Physical ex-
amination was unremarkable. A complete blood count showed a white blood cell (WBC) count of 5600 with
normal differential; a platelet count was 150,000, and a hemoglobin of 8.9. The erythrocyte mean corpuscular
volume was 106. Iron, B12, and folate studies were normal. An erythropoietin level was reported at 500 units
(markedly elevated).
The bonemarrowwas hypercellular for age,M:E ratio 3:1, withmild reticulin fibrosis. The erythroid serieswas
left shiftedwith dyserythropoiesis.Themyeloid serieswas slightly left shiftedwithpseudo-Pelger-Huet abnor-
malities present. Megakaryocytes appeared normal in morphology and number. Myeloblast count was esti-
mated at 7%. Iron stores were increased; there was no increase in ring sideroblasts. Flow cytometry showed
a CD341 blast population of 9% and maturing myeloid cells with aberrant expression of CD33, HLA-DR,
and CD56. Cytogenetic analysis showed the following karyotype: 47, XY, 18, 20q-, -Y [11]; 46, XY [9].
The patient has 2 healthy siblings, 56 and 62 years of age. HLA typing is being arranged.
What would you recommend?
 Treat with a DNA methyltransferase inhibitor (Vidaza or Dacogen)
 Treat with Lenalidomide
 Observe, and treat with packed red blood cell (RBC) as needed for symptoms
Further developments: HLA typing results are now available. What would you recommend?
 Transplantation with a conventional conditioning regimen, only if a sibling is HLA identical
 Transplantation with a reduced-intensity conditioning (RIC) regimen, only if a sibling is HLA identical
 Transplantation with a conventional conditioning regimen, from either an HLA-identical sibling or an
unrelated donor
 Transplantation with an RIC regimen, from either an HLA-identical sibling or an unrelated donor
 No transplantation nowREADER RESPONSES
In a recent issue of the ASBMT eNEWS, readers
were presented with the above Clinical Challenge and
invited to use an online poll to recommend a course of
treatment. The reader recommendations for therapy
were:
 50% Treat with a DNA methyltransferase inhibitor
(Vidaza or Dacogen)
 35%Observe, and treat with packed RBC as needed
for symptoms
 15% Treat with Lenalidomid
Further developments:
 30% Transplantation with an RIC regimen, only if
a sibling is HLA identical
 30% No transplantation now
 26% Transplantation with an RIC regimen, from
either an HLA-identical sibling or an unrelated
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6/j.bbmt.2008.05.014 9% Transplantation with a conventional condition-
ing regimen, from either an HLA-identical sibling
or an unrelated donor
 5% Transplantation with a conventional condition-
ing regimen, only if a sibling is HLA identicalCOMMENTARY
Myelodysplastic syndromes (MDS) is a disease of
older patients, and the course is frequently protracted,
often leading to conservative management. The devel-
opment of scoring systems such as the IPSS (orWPSS)
has been useful in guiding physicians and patients, and
the approval by the U.S. Food and Drug Administra-
tion of several compounds for the treatment of
subgroups of patients with MDS has brightened the
outlook.
By IPSS criteria the patient under discussion is
scored as follows: 0.5 for myeloblasts, 0 for cytopenias,
and 0.5 or 1.0 for his karyotype (dependent upon
whether we consider the loss of the Y chromosome
in 11 of 20 cells as age related or as clonal) for a total
score of 1 or 1.5, that is, risk group intermediate 11001
1002 H. J. Deeg(median life expectancy 5 years) or 2 (median life ex-
pectancy 1.5-2 years) [1]. Based on the results of a deci-
sion analysis by Cutler et al. [2], this places the patient
in the gray zone between conservative management
and transplantation.
Transfusion with packed red blood cells only was
selected by 35% of respondents to our Clinical Chal-
lenge, but is not expected to have a favorable impact
on the disease course. The use of lenalidomide was
recommended by 15% of respondents. In transfusion-
dependent patients without del (5q), lenalidomide re-
sulted in transfusion independence in 26% of patients
for a median duration of 10 months; no significant
improvements in karyotypes were observed [3] (and
the drug is currently not approved for this indication).
The response rates with DNA methyltransferase
inhibitors have been in the range of 30% to 60% in
patients with ‘‘advanced’’ MDS, and recent data sug-
gest that survival is prolonged [4]. Half of respondents
recommended this therapy. Conceivably, results are
further improved with incorporation of etanercept (to
neutralize TNF-a-mediated signals) into the regimen.
Currently the only strategy with the potential of
curing the disease is hematopoietic cell transplantation
(HCT). In view of the patient’s young age and the
karyotype, HCT from anHLA-identical related or un-
related donor should be considered as recommended
by 70% of respondents. We prefer related donors,
but results with unrelated donors are comparable
(except for a higher incidence of graft-versus-host dis-
ease [GVHD]) [5]. The ideal conditioning regimen has
yet to be determined. In patients with elevated myelo-
blast counts, higher dose regimens may be associated
with a lower probability of relapse, but only retrospec-
tive analyses are available; a randomized study has been
initiated. Similarly, there are no prospective data as to
the benefit of pre-HCT debulking therapy. Studies are
under way to determine whether DNA methyltrans-
ferase inhibitors given before HCT may lead to a re-
duced relapse incidence without increasing toxicity.
Of the respondents recommending HCT, almost
80% favored a reduced-intensity (RIC) preparativeregimen. It should be noted that many of the so-called
‘‘myeloablative’’ regimens have been modified and
early (regimen-related) mortality may not differ from
that seen with ‘‘nonmyeloablative’’ regimens. In Seat-
tle, patients up to 60 years of age who do not have clin-
ically significant comorbid conditions are usually
treated with the ‘‘myeloablative’’ regimens currently
in use (eg, targeted Bu 1 Flu; targeted Bu 1 Cy;
Melphalan1 Flu, and others). The probability of sur-
vival in remission should be about 50% [6].
Importantly, this case again illustrates that pro-
spective trials are needed to define optimal treatment
approaches.
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